Park Ha Biological Technology Co., Ltd. shares rise 2.49% premarket after Opus Genetics announces IRD gene therapy programs presentation.

Park Ha Biological Technology Co., Ltd. rose 2.49% in premarket trading. Opus Genetics, Inc. announced that it will present on its IRD gene therapy programs at the Ophthalmology Futures Forum in Paris, France on September 3, 2025. The company's Senior Vice President Clinical Development, Sally Tucker, Ph.D., will participate in a panel discussion titled "Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress" and deliver a corporate presentation later that day.